Janney Capital Management LLC Has $8.92 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Janney Capital Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,928 shares of the medical research company’s stock after selling 226 shares during the quarter. Janney Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $8,921,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. FPC Investment Advisory Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Pillar Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Finally, Noble Wealth Management PBC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $35,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $392.54 on Thursday. The company has a market capitalization of $148.18 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.06 and a beta of 0.78. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The stock has a fifty day simple moving average of $414.12 and a 200 day simple moving average of $489.73. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the business posted $5.11 EPS. The business’s revenue was up .2% compared to the same quarter last year. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.44%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TMO shares. Argus reduced their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. UBS Group reduced their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Finally, Evercore ISI reduced their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.